Vor Bio to Participate in Upcoming Investor Conferences
01 avr. 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
20 mars 2024 16h05 HE
|
Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 mars 2024 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...
Vor Bio to Participate in Upcoming Investor Conferences
04 mars 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 févr. 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2024 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 janv. 2024 16h01 HE
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 déc. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the...
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
27 nov. 2023 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...